Abstract:Abstract Abstract 205 Somatic cell reprogramming into a pluripotent state by the so called “iPS” technology not only holds great promise in regenerative medicine, but also provides a powerful tool to study pathological dedifferentiation processes such as tumorigenesis. In fact, the four “Yamanaka” reprogramming transcription factors used for iPS induction (Oct4, Sox2, and especially C-Myc and KLF4) are known for their direct or indirect oncogenic activities. In addition, the two most well-known tumor suppressor pathways, p53 and Rb, have been shown to also suppress iPS reprogramming. These suggest that tumorigenesis and somatic cell reprogramming may share some common mechanisms. Although it was previously reported that malignant cell lines or primary cancer cells could be reprogrammed by nuclear transfer or the iPS approach, it has not been definitively demonstrated whether primary transformed cells (not established tumor cell lines) can be reprogrammed into iPS cells with a full-term developmental potential in vivo. To this end, we first established an acute myeloid leukemia (AML) mouse model by over-expressing the human MLL (mixed lineage leukemia)-AF9 fusion gene in hematopoietic cells harvested from transgenic mice that carry the Yamanaka reprogramming factors under the control of doxycycline (Dox) (Brambrink et al., 2008). We chose MLL leukemia (a group of aggressive forms of acute leukemia with poor prognosis) because the genome of MLL leukemic cells was shown to be relatively stable, thereby increasing the likelihood of successful reprogramming of the leukemic nuclei. The purified leukemic cells were then induced into iPS cells by an addition of Dox under mouse embryonic stem cell (ESC) culture conditions. The MLL-AF9 fusion gene was present in all the iPS colonies, but its expression was silent in the established iPS cell lines. The generated iPS cell lines were similar to normal ES cells lines, as shown by both genetic and epigenetic signatures. The MLL-AF9 iPS cell lines could give rise to teratomas consisting of three germ layers after injection into a SCID mouse. More importantly, some MLL-AF9 iPS cell lines were able to produce chimeras at a high rate through blastocyst injection. Noticeably however, most chimeras developed the same type of AML within 2 months, which was correlated with re-activation of the MLL-AF9 gene. Consistently, DNA methylation of a MLL-AF9 promoter differed significantly between original leukemic cells, derived iPS cells and the re-occurred leukemic cells from the chimera mice, for which the de novo DNA methtylase, DNA3b, rather than other methylating enzymes, seemed to be responsible. RNA-seq analysis is under way to further define the target genes involved in the differences of these interchangeable cell types. In summary, this study demonstrates for the first time that primary leukemia cells can be fully reprogrammed into iPS cells with the potential of developing into three germ layers and contributing to chimeric mice. The interchangeable feature between leukemic cells and iPS cells offers a unique opportunity to define the distinct mechanisms between pluripotency and malignancy, thereby having implications for specific manipulations of iPS vs. cancer cells and particularly for selective targeting of the leukemic cells harboring a MLL fusion gene. Disclosures: No relevant conflicts of interest to declare.

Foxo3a Contributes to the Reprogramming Process and the Differentiation of Induced Pluripotent Stem Cells

Forkhead Box Family Transcription Factors As Versatile Regulators for Cellular Reprogramming to Pluripotency.

Foxm1 Mediates LIF/Stat3-Dependent Self-Renewal in Mouse Embryonic Stem Cells and is Essential for the Generation of Induced Pluripotent Stem Cells

Reprogrammed Mouse Astrocytes Retain a “memory” of Tissue Origin and Possess More Tendencies for Neuronal Differentiation Than Reprogrammed Mouse Embryonic Fibroblasts

Brief Report: Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts

Foxd3 suppresses NFAT-mediated differentiation to maintain self-renewal of embryonic stem cells.

Foxm1 Transcription Factor is Required for Maintenance of Pluripotency of P19 Embryonal Carcinoma Cells

Reprogrammed Astrocytes As a Potential Therapy for Neurodegenerative Disorders.

Foxa1 contributes to the repression of Nanog expression by recruiting Grg3 during the differentiation of pluripotent P19 embryonal carcinoma cells.

FOXD3 controls pluripotency through modulating enhancer activity.

Expression and Activation of the Reprogramming Transcription Factors

Tbx3 improves the germ-line competency of induced pluripotent stem cells

A novel role for an RNA polymerase III subunit POLR3G in regulating pluripotency in human embryonic stem cells

Synergetic Cooperation Of Micrornas With Transcription Factors In Ips Cell Generation

Stimulation of Somatic Cell Reprogramming by ERas-Akt-FoxO1 Signaling Axis.

Sox2 and Klf4 as the Functional Core in Pluripotency Induction without Exogenous Oct4.

JAK-STAT3 and Somatic Cell Reprogramming.

Knockdown of FoxO3a Induces Increased Neuronal Apoptosis During Embryonic Development in Zebrafish

Role of Mef Feeder Cells in Direct Reprogramming of Mouse Tail-Tip Fibroblasts

Dppa3 expression is critical for generation of fully reprogrammed iPS cells and maintenance of Dlk1-Dio3 imprinting

Reprogramming of MLL-AF9 Leukemic Cells into Pluripotent Stem Cells in Mice